HANSOH PHARMA(03692.HK): NDA for HS-10568 Injection Accepted by NMPA for Secondary Hyperparathyroidism in Dialysis Patients

NewTimeSpace · 2026/06/10 18:48 · By Zeyu Wu

NewTimeSpace News: Hansoh Pharmaceutical Group Company Limited (03692.HK) announced that the New Drug Application (NDA) for its innovative drug HS-10568 Injection (partner code: SHR6508) was accepted by the National Medical Products Administration (NMPA) on June 9, 2026. It is indicated for secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease undergoing hemodialysis. HS-10568 is an allosteric modulator of calcium-sensing receptor (CaSR).

NewTimeSpaceNews: Hansoh Pharmaceutical Group Company Limited (03692.HK) issued a voluntary announcement on June 10, 2026. The New Drug Application for its innovative drug HS-10568 Injection (partner code: SHR6508) was accepted by the National Medical Products Administration of China on June 9, 2026. The product is intended for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) receiving hemodialysis.

As an allosteric modulator of calcium-sensing receptor (CaSR), HS-10568 can enhance the receptor's sensitivity to extracellular calcium, thereby inhibiting the secretion of parathyroid hormone (PTH).

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

HANSOH PHARMA 03692.HK New Drug Application